{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:46:18Z","timestamp":1793094378795,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.eururo.2015.08.034","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T15:13:19Z","timestamp":1441293199000},"page":"855-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":252,"title":["A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na\u00efve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer"],"prefix":"10.1016","volume":"69","author":[{"given":"David J.","family":"McConkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.-Ling","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Porten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall E.","family":"Millikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Czerniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.08.034_bib0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.08.034_bib0140","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eururo.2012.08.010","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma\u2014neoadjuvant and adjuvant settings","volume":"63","author":"Sternberg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0155","first-page":"4866","article-title":"The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy","volume":"6","author":"Inoue","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.08.034_bib0160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.ju.0000108845.91485.20","article-title":"Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy","volume":"171","author":"Slaton","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0165","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0170","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0022-5347(05)68936-7","article-title":"Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort","volume":"161","author":"Bassi","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1046\/j.1464-410x.1998.00637.x","article-title":"Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients","volume":"81","author":"Wijkstrom","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0180","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0185","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncr.27751","article-title":"A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results","volume":"119","author":"Siefker-Radtke","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.08.034_bib0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2015.08.034_bib0195","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2015.08.034_bib0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2015.08.034_bib0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1198\/016214502753479248","article-title":"Comparison of discrimination methods for the classification of tumors using gene expression data","volume":"97","author":"Dudoit","year":"2002","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2015.08.034_bib0210","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.08.034_bib0215","doi-asserted-by":"crossref","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2015.08.034_bib0220","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0225","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0230","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1464-410X.2011.10582.x","article-title":"Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)","volume":"108","author":"Scosyrev","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.08.034_bib0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2015.08.034_bib0240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrclinonc.2011.178","article-title":"Practical implications of gene-expression-based assays for breast oncologists","volume":"9","author":"Prat","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0245","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrurol.2012.142","article-title":"Normal and neoplastic urothelial stem cells: getting to the root of the problem","volume":"9","author":"Ho","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0250","doi-asserted-by":"crossref","first-page":"e30206","DOI":"10.1371\/journal.pone.0030206","article-title":"p63 expression defines a lethal subset of muscle-invasive bladder cancers","volume":"7","author":"Choi","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.eururo.2015.08.034_bib0255","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ajpath.2010.11.061","article-title":"Distinct expression profiles of p63 variants during uothelial development and bladder cancer progression","volume":"178","author":"Karni-Schmidt","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2015.08.034_bib0260","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815007794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815007794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T19:21:03Z","timestamp":1537384863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815007794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0302283815007794"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.08.034","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na\u00efve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}